EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG

View source ↗

Summary

EMA authorised Hukyndra (adalimumab) from Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, juvenil…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Juvenile Idiopathic Arthritis
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• Hukyndra (adalimumab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Psoriatic;Arthritis, Juvenile Rheumatoid;Arthritis, Rheumatoid;Colitis, Ulcerative;Crohn Disease;Hidradenitis Suppurativa;Psoriasis;Spondylitis, Ankylosing;Uveitis. MAH: Stada Arzneimittel AG. Decision date: 28/01/2026